Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nutra Pharma has announced that its wholly-owned drug discovery subsidiary, ReceptoPharm, has successfully completed the Phase IIb/IIIa clinical trial of its leading drug candidate for neurological and autoimmune disorders, RPI-78M, as a treatment for adrenomyeloneuropathy.
Subscribe to our email newsletter
The company has applied for orphan drug status in the US and intends doing so for the EU. ReceptoPharm expects to present the clinical findings from the study by the end of September 2008.
Paul Reid, CEO of ReceptoPharm, said: “Completing this clinical trial is an important achievement for both Nutra Pharma and ReceptoPharm. Our next step is to compile, analyze and present the results from this trial to the medical community.”